Reading the Methylation Map

How DNA methylation profiling is refining tumor classification and helping pathology deliver more personalized patient management

By
Helen Bristow
November 12, 2026
8 min

The Pathologist

At a Glance

Category	Detail
Condition	Clinical topic addressed by the source article: Reading the Methylation Map
Key Mechanisms	Mechanisms or clinical associations described in the source article.
Target Population	Patients or participants described in the source article.
Care Setting	The interviewee describes a proposed two-tier approach: routine pathology may identify cases for referral to expert centers or networks for further molecular testing and, where appropriate, a second opinion. The source says whether testing will be centralized or decentralized remains open.

Key Highlights

The interviewee reports that the WHO classification recognizes more than 150 tumor classes and that methylation-based classification is required for accurate identification of some tumor classes.
Methylation profiling can support disease classification and may inform management, including watch-and-wait, treatment timing, therapy selection, or avoiding unnecessary treatment.
The interviewee describes methylation profiling as complementary to established pathology, not a replacement for conventional workflows.
Image-based analysis of H&E slides is being explored to help identify cases that may benefit from further molecular classification.
Testing access may depend on scale, sample logistics, platform affordability, and healthcare-system context; the interviewee says the preferred model is not yet known.

Guideline-Based Recommendations

Diagnosis

According to the interviewee, methylation-based classification is required for accurate identification of some tumor classes.
The interviewee describes methylation profiling as potentially useful when established pathology does not distinguish tumor classes.

Management

The interviewee says classification information may inform management, including watch-and-wait, treatment timing, therapy selection, or avoiding unnecessary treatment.
The interviewee describes methylation profiling as integrating with, rather than replacing, established pathology.

Monitoring & Follow-up

Risks

The interviewee notes that unnecessary treatment can cause associated side effects and that long-term effects are particularly important for very young patients.

Patient & Prescribing Data

Selected patients requiring more precise tumor classification, including patients with CNS tumors and pediatric brain tumors.

Methylation-based classification may inform whether to escalate or de-escalate management, treatment timing, or therapy selection; the article does not provide drug-specific prescribing data.

Clinical Best Practices

The interviewee says H&E staining and conventional pathology will remain the foundation of diagnosis.
The interviewee describes routine pathology and image-based analysis as possible ways to triage cases for specialized molecular characterization.
The interviewee describes referral to expert centers or networks for further testing and, where appropriate, a second opinion.
The interviewee says centralized and decentralized testing are both possibilities and that the preferred model may differ between healthcare systems.